P. Johnson

发表

The development of non-steroidal dual inhibitors of both human 5α-reductase isozymes

P. Finn, J. Blagg, F. Macintyre, 1996 .

Topical 'dual-soft' glucocorticoid receptor agonist for dermatology.

K. Dack, A. Ollerstam, M. Stahlhut, 2020, Bioorganic & medicinal chemistry letters.

4-Cyanophenols bearing metabolically robust substituents

T. Underwood, P. Johnson, S. Wheeler, 2011 .

Improved Method for the Preparation of Oxadiazoles from Diacyl Hydrazines

D. Ellis, Andrew Nortcliffe, P. Johnson, 2010 .

Preparation of triazolobenzodiazepine derivatives as Vasopressin V1a antagonists

T. Ryckmans, J. Bryans, T. Peakman, 2011 .

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

M. Gleave, A. Zoubeidi, A. Fanjul, 2011, Journal of medicinal chemistry.

Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.

M. Andrews, Malcolm C. Mackenny, M. J. Pitcher, 2006, Bioorganic & medicinal chemistry letters.

Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1

M. Trevethick, Alan S. Jessiman, Carly L. Nichols, 2006 .

Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.

M. Andrews, Malcolm C. Mackenny, D. Hepworth, 2008, Bioorganic & medicinal chemistry letters.